Imperial College London
Portrait Picture

MrStefanAntonowicz

Faculty of Medicine, Department of Surgery & Cancer

Clinical Senior Lecturer in Upper Gastro Surgery
 
 
 
//

Contact

 

s.antonowicz Website

 
 
//

Location

 

1st Floor B-BlockBlock B Hammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Savva:2022:10.1158/1055-9965.EPI-22-0307,
author = {Savva, K-V and Das, B and Antonowicz, S and Hanna, GB and Peters, CJ},
doi = {10.1158/1055-9965.EPI-22-0307},
journal = {Cancer Epidemiology, Biomarkers and Prevention},
pages = {2095--2105},
title = {Progress with metabolomic blood tests for gastrointestinal cancer diagnosis-an assessment of biomarker translation},
url = {http://dx.doi.org/10.1158/1055-9965.EPI-22-0307},
volume = {31},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - There is an urgent need for cost-effective, non-invasive tools to detect early stages of gastrointestinal cancer (colorectal, gastric, and esophageal cancers). Despite many publications suggesting circulating metabolites acting as accurate cancer biomarkers, few have reached the clinic. In upper gastrointestinal cancer this is critically important, as there is no test to complement gold-standard endoscopic evaluation in patients with mild symptoms that do not meet referral criteria. Therefore, this study aimed to describe and solve this translational gap. Studies reporting diagnostic accuracy of metabolomic blood-based gastrointestinal cancer biomarkers from 2007 to 2020 were systematically reviewed and progress of each biomarker along the discovery–validation–adoption pathway was mapped. Successful biomarker translation was defined as a composite endpoint, including patent protection/FDA approval/recommendation in national guidelines. The review found 77 biomarker panels of gastrointestinal cancer, including 25 with an AUROC >0.9. All but one was stalled at the discovery phase, 9.09% were patented and none were clinically approved, confirming the extent of biomarker translational gap. In addition, there were numerous “re-discoveries,” including histidine, discovered in 7 colorectal studies. Finally, this study quantitatively supports the presence of a translational gap between discovery and clinical adoption, despite clear evidence of highly performing biomarkers with significant potential clinical value.
AU  - Savva,K-V
AU  - Das,B
AU  - Antonowicz,S
AU  - Hanna,GB
AU  - Peters,CJ
DO  - 10.1158/1055-9965.EPI-22-0307
EP  - 2105
PY  - 2022///
SN  - 1055-9965
SP  - 2095
TI  - Progress with metabolomic blood tests for gastrointestinal cancer diagnosis-an assessment of biomarker translation
T2  - Cancer Epidemiology, Biomarkers and Prevention
UR  - http://dx.doi.org/10.1158/1055-9965.EPI-22-0307
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000892740300001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
UR  - https://aacrjournals.org/cebp/article/31/12/2095/711123/Progress-with-Metabolomic-Blood-Tests-for
UR  - http://hdl.handle.net/10044/1/102063
VL  - 31
ER  -
Download